SBMFF (Sino Biopharmaceutical) Common Stock: $59 Mil (As of Dec. 2025)


SBMFF Sino Biopharmaceutical Ltd SBMFF
62 GF Score
Price $0.64
GF Value $0.61
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Sino Biopharmaceutical Common Stock?

Sino Biopharmaceutical SBMFF -1.07% 62 Common Stock is $59 Mil as of Dec. 2025. GuruFocus rates SBMFF with a GF Score™ of 62/100 and a GF Value™ of $0.61 (Fairly Valued). The stock has 4 warning signs investors should review.

Sino Biopharmaceutical's quarterly common stock increased from Dec. 2024 ($57 Mil) to Jun. 2025 ($58 Mil) and increased from Jun. 2025 ($58 Mil) to Dec. 2025 ($59 Mil).

Sino Biopharmaceutical's annual common stock declined from Dec. 2023 ($58 Mil) to Dec. 2024 ($57 Mil) but then increased from Dec. 2024 ($57 Mil) to Dec. 2025 ($59 Mil).

Sino Biopharmaceutical Common Stock Historical Data

* Premium members only.

The historical data trend for Sino Biopharmaceutical's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sino Biopharmaceutical Common Stock Chart

Sino Biopharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.23 59.51 58.07 56.92 58.73

Sino Biopharmaceutical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.07 57.12 56.92 57.61 58.73
SBMFF
62GF Score
Sino Biopharmaceutical Ltd SBMFF
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sino Biopharmaceutical Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $59 Mil mean?
Sino Biopharmaceutical (SBMFF) has a Common Stock of $59 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Sino Biopharmaceutical and its competitors.
Is Sino Biopharmaceutical's Common Stock too high?
Sino Biopharmaceutical's current Common Stock is $59 Mil. Overall, Sino Biopharmaceutical has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's Common Stock compare to VRTX and REGN?
Sino Biopharmaceutical's Common Stock of $59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current Common Stock is $59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.61, compared to a current price of $0.64 — trading 4.4% above its estimated fair value. The current Common Stock is $59 Mil. Sino Biopharmaceutical's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current Common Stock is $59 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?

Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be overvalued. The current stock price of $0.64 is trading 4.4% above its estimated GF Value™ of $0.61. GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.

Key valuation signals for SBMFF:

  • Common Stock: $59 Mil
  • GF Value™: $0.61 vs. price of $0.64 (4.4% above fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sino Biopharmaceutical Business Description

Address 1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
62GF Score

Get the complete analysis for SBMFF

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64
Price
$0.61
GF Value